Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2008 on Tuesday, May 6, 2008 at approximately 8:00 a.m. (ET). The...

ALLEGAN, Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for over-the-counter...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), has received final approval from the U.S. Food and Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's Chairman and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device...

-- Second quarter revenue increased $65 million, or 17 percent, to $435 million -- GAAP net income increased 63 percent to $34 million, or $0.36 per share -- Second quarter cash provided by...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2008 on Tuesday, February 5, 2008 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors appointed President and Chief Executive Officer, Joseph C. Papa, to be Chairman of its Board of Directors....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on December 18, 2007 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2008 on Thursday, November 1, 2007 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that President and CEO, Joseph C. Papa and the Perrigo management team will provide a review of the Company business for the financial...